Non-proteolytic neurotrophic effects of tissue plasminogen activator on cultured mouse cerebrocortical neurons

被引:37
作者
Lee, Hee-Young
Hwang, Ih-Yeon
Im, Hana
Koh, Jae-Young
Kim, Yang-Hee
机构
[1] Sejong Univ, Dept Biol Mol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, NRL Neural Injury Res Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Dept Neurol, Seoul, South Korea
关键词
annexin-II; intracellular signaling kinases; neurite outgrowth; neuronal survival;
D O I
10.1111/j.1471-4159.2007.04417.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Most biological effects of tissue plasminogen activator (tPA), such as fibrinolysis, are mediated by its protease activity. Recent studies, however, have demonstrated that tPA also has several protease-independent effects such as: neuroprotection, microglial activation, and promoting LTP formation. In order to gain a better understanding of how tPA affects neurons, we examined neurite outgrowth and cell survival in low density cerebrocortical neuronal culture in the presence of tPA. tPA enhanced neurite elongation and neuronal survival. tPA protease inhibitors, PAI-1 or PMSF, did not alter either effect. Consistent with neurotrophic effects, tPA activated Raf-K/ERK, PKC and PI3-K/Akt, 5-60 min after treatment. In addition, specific inhibitors of these kinases reduced tPA-induced neurite outgrowth. Interestingly, survival-promoting effect of tPA was attenuated only by PI3-K inhibitors. Activation of signaling kinases suggests that tPA activates an upstream membrane receptor. Thus far, three membrane proteins, low density lipoprotein receptor-related protein (LRP), mannose receptor (MR), and annexin-II (AII), have been identified to bind tPA. While inhibiting LRP or MR did not change tPA-induced neurite outgrowth and cell survival, inhibiting AII blocked neurotrophic effects of tPA. Taken together, our results indicate that tPA has novel, non-proteolytic neurotrophic effects on cultured cortical neurons, which are likely mediated by AII.
引用
收藏
页码:1236 / 1247
页数:12
相关论文
共 54 条
[1]  
BarrettBergshoeff M, 1997, THROMB HAEMOSTASIS, V77, P718
[2]   Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding [J].
Bellagamba, C ;
Hubaishy, I ;
Bjorge, JD ;
Fitzpatrick, SL ;
Fujita, DJ ;
Waisman, DM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (06) :3195-3199
[3]   LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR IS AN HEPATIC RECEPTOR FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
BU, GJ ;
WILLIAMS, S ;
STRICKLAND, DK ;
SCHWARTZ, AL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (16) :7427-7431
[4]   Neuroprotective effects of L-arginine administration after cortical impact injury in rats: Dose response and time window [J].
Cherian, L ;
Chacko, G ;
Goodman, C ;
Robertson, CS .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (02) :617-623
[5]  
CHOI DW, 1987, J NEUROSCI, V7, P357
[6]   QUALITATIVE AND QUANTITATIVE DISTRIBUTION OF PLASMINOGEN ACTIVATORS IN ORGANS FROM HEALTHY ADULT MICE [J].
DANGLOT, G ;
VINSON, D ;
CHAPEVILLE, F .
FEBS LETTERS, 1986, 194 (01) :96-100
[7]   UROKINASE-TYPE AND TISSUE-TYPE PLASMINOGEN ACTIVATORS AS GROWTH-FACTORS OF HUMAN FIBROBLASTS [J].
DEPETRO, G ;
COPETA, A ;
BARLATI, S .
EXPERIMENTAL CELL RESEARCH, 1994, 213 (01) :286-294
[8]   Is tissue-type plasminogen activator a neuromodulator? [J].
Fernández-Monreal, M ;
López-Atalaya, JP ;
Benchenane, K ;
Léveillé, F ;
Cacquevel, M ;
Plawinski, L ;
MacKenzie, ET ;
Bu, GJ ;
Buisson, A ;
Vivien, D .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2004, 25 (04) :594-601
[9]   Tissue plasminogen activator binding to the annexin II tail domain - Direct modulation by homocysteine [J].
Hajjar, KA ;
Mauri, L ;
Jacovina, AT ;
Zhong, FM ;
Mirza, UA ;
Padovan, JC ;
Chait, BT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9987-9993
[10]   THE ANNEXINS - SPECIFIC MARKERS OF MIDLINE STRUCTURES AND SENSORY NEURONS IN THE DEVELOPING MURINE CENTRAL-NERVOUS-SYSTEM [J].
HAMRE, KM ;
CHEPENIK, KP ;
GOLDOWITZ, D .
JOURNAL OF COMPARATIVE NEUROLOGY, 1995, 352 (03) :421-435